` EDT (Spectral Medical Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

EDT
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, EDT has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +62% compared to the S&P TSX Composite Index (Canada)'s +20% growth.

Stocks Performance
EDT vs S&P TSX Composite Index (Canada)

Loading
EDT
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
EDT vs S&P TSX Composite Index (Canada)

Loading
EDT
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
EDT vs S&P TSX Composite Index (Canada)

Loading
EDT
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Spectral Medical Inc vs Peers

S&P TSX Composite Index (Canada)
EDT
ABBV
AMGN
GILD
VRTX
Add Stock

Spectral Medical Inc
Glance View

Market Cap
230.9m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
0.04 CAD
Overvaluation 95%
Intrinsic Value
Price
Back to Top